Phase 1B Study to Assess Safety and Efficacy of Neo-Adjuvant Bladder Urothelial Carcinoma COmbination-immunotherapy (NABUCCO)
Latest Information Update: 05 Jul 2024
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Bladder cancer; Carcinoma; Urogenital cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms NABUCCO
- 04 Jun 2024 Results assessing an update on clinical efficacy and an exploratory biomarker analysis were presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
- 01 Mar 2023 Results assessing High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer published in the Nature Medicine
- 08 Feb 2023 Results published in the NeoGenomics Media Release.